Time-varying impact of anti-viral therapy on liver stiffness in patients with hepatitis B is unclear.
To estimate the magnitude and kinetics of change in liver stiffness in hepatitis B patients treated with nucleot(s)ide analogs.
Through a systematic review of multiple databases, we identified 24 studies in adults with hepatitis B who underwent transient elastography before and at least 6 months after starting nucleot(s)ide analogs therapy. We estimated change in liver stiffness 6 m, 12 m, 24 m, 36 m and 60 m after starting therapy, as weighted mean difference and 95% confidence intervals, using random-effects meta-analysis.
Liver stiffness significantly declined by 2.21 kPa (95% CI, −1.36 to −3.05), 2.56 kPa (−2.23 to −2.89), 3.73 kPa (−2.98 to −4.49), 4.15 kPa (−2.75 to −5.54), and 5.19 kPa (−3.34 to −7.03) at 6 months, 1 year, 2 years, 3 years, and 5 years from the start of therapy, respectively (p < 0.001). High baseline alanine aminotransferase level, viral load and liver stiffness were associated with greater magnitude of decline in liver stiffness.
Antiviral therapy is associated with progressive decline in liver stiffness in patients with hepatitis B, particularly in patients with high baseline alanine aminotransferase and viral load.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Digestive and Liver Disease
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Hepatitis B virus infection.Lancet. 2009; 373: 582-592
- Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.Lancet. 2015; 386: 1546-1555
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.Lancet. 2013; 381: 468-475
- Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.J Hepatol. 2010; 53: 348-356
- Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B.Clin Gastroenterol Hepatol. 2011; 9: 274-276
- Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.Hepatology. 2010; 52: 886-893
- American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases.Gastroenterology. 2017; 152: 1544-1577
- Improvement of liver fibrosis after long-Term antiviral therapy assessed by Fibroscan in chronic hepatitis B patients with advanced fibrosis.Am J Gastroenterol. 2017; 112: 882-891
- Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog.Hepatol Res. 2011; 41: 1178-1188
- Reduction of liver stiffness by antiviral therapy in chronic hepatitis B.J Gastroenterol. 2011; 46: 1324-1334
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.Syst Rev. 2015; 4: 1
- Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol. 2015; 13: 643-654
- Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis.Clin Gastroenterol Hepatol. 2017; (pii: S1542-3565(17)30532-3)
- Higgins J.P.T. Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration,
2011 (Available from)www.handbook.cochrane.org
- Dynamic changes in liver stiffness measured by transient elastography predict clinical outcomes among patients with chronic hepatitis B.J Ultrasound Med. 2017; 36: 261-268
- Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: Regression of liver stiffness during entecavir therapy.Hepatol Res. 2010; 40: 853-861
- Mild-to-moderate elevation of alanine aminotransferase increases liver stiffness measurement by transient elastography in patients with chronic hepatitis B.Am J Gastroenterol. 2011; 106: 492-496
- Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study.J Viral Hepat. 2011; 18: e200-e205
- The diagnostic value of ultrasound elastography in patients with hepatitis B virus infection: a prospective study.J Int Med Res. 2010; 38: 2117-2125
- Effect of antiviral treatment on liver stiffness and its correlation to hepatocarcinogenesis in chronic hepatitis B.Hepatology. 2014; 60: 4112A
- Assessment of hepatic fibrosis regression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agents.J Korean Med Sci. 2014; 29: 570-575
- Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir.Liver Int. 2014; 34: 1216-1223
- Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression.Hepatol Int. 2010; 4: 673-680
- Assessment of treatment response by elastography during the tenofovir treatment in nucleos(t)ide-naïve chronic hepatitis B patients.Hepatology. 2015; 62: 1001A
- Changes in liver stiffness measurement during antiviral therapy in patients with chronic hepatitis B.Hepatogastroenterology. 2011; 58: 539-545
- Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: a preliminary study.Eur J Pharmacol. 2017; 806: 105-109
- Five-year on-treatment systematically monitoring of dynamic changes of liver stiffness measurement with transient elastography compared with paired liver biopsies in chronic hepatitis B patients.J Hepatol. 2016; 64: S133-S134
- Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.J Gastroenterol Hepatol. 2016; 31: 1307-1314
- On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients.Antivir Ther. 2011; 16: 165-172
- Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: a prospective cohort study with paired transient elastography examination.J Gastroenterol Hepatol. 2013; 28: 1762-1769
- Impact of mild to moderate elevations of alanine aminotransferase on liver stiffness measurement in chronic hepatitis B patients during antiviral therapy.Hepatol Res. 2013; 43: 185-191
- Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks.Eur J Gastroenterol Hepatol. 2014; 26: 396-403
- Relationships between transient elastography values and liver fibrosis in chronic liver disease patients with normal or mildly abnormal aminotransferase levels.Genet Mol Res. 2015; 14: 18172-18180
- Serum WFA+-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection.Liver Int. 2017; 37: 35-44
- 2-years impact of entecavir (ETV) on liver fibrosis and activity as assessed by FibroTest – ActiTest and Liver Stiffness Measurement (LSM) in chronic hepatitis B (CHB) patients.Hepatology. 2014; 60: 1126A
- Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy.Am J Gastroenterol. 2014; 109: 1241-1249
- Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy.Liver Int. 2013; 33: 180-189
- The long-term benefi ts of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study.J Hepatol. 2015; 63: 1118-1125
- Histological outcome during long-term lamivudine therapy.Gastroenterology. 2003; 124: 105-117
Published online: May 15, 2018
Accepted: May 5, 2018
Received in revised form: April 27, 2018
Received: February 12, 2018
© 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.